Cost-effectiveness of Check It: A Novel Community-Based Chlamydia Screening and Expedited Treatment Program for Young Black Men

Clin Infect Dis. 2022 Jul 6;74(12):2166-2172. doi: 10.1093/cid/ciab818.

Abstract

Background: We assessed the cost-effectiveness of the Check It program, a novel community-based chlamydia screening and expedited partner treatment program for young Black men conducted in New Orleans since 2017.

Methods: We implemented a probabilistic cost-effectiveness model using a synthetic cohort of 16 181 men and 13 419 women intended to simulate the size of the Black, sexually active population in New Orleans ages 15-24 years.

Results: The Check It program cost $196 838 (95% confidence interval [CI]: $117 320-$287 555) to implement, saved 10.2 quality-adjusted life-years (QALYs; 95% CI: 7.7-12.7 QALYs), and saved $140 950 (95% CI: -$197 018 to -$105 620) in medical costs per year. The program cost $5468 (95% CI: cost saving, $16 717) per QALY gained. All iterations of the probabilistic model returned cost-effectiveness ratios less than $50 000 per QALY gained.

Conclusions: The Check It program (a bundled seek, test, and treat chlamydia prevention program for young Black men) is cost-effective under base case assumptions. Communities where Chlamydia trachomatis rates have not declined could consider implementing a similar program.

Keywords: chlamydia; cost-effective; expedited partner treatment; screening.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adolescent
  • Adult
  • Chlamydia Infections* / diagnosis
  • Chlamydia Infections* / drug therapy
  • Chlamydia Infections* / epidemiology
  • Chlamydia trachomatis
  • Cost-Benefit Analysis
  • Female
  • Humans
  • Male
  • Mass Screening
  • Quality-Adjusted Life Years
  • Young Adult